Improving diagnosis and treatment of Myelodysplastic Syndromes in Spain
Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)
This study is trying to improve how doctors diagnose and treat Myelodysplastic Syndromes in Spain by using new techniques to find genetic changes in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Instituto de Investigación Biomédica de Salamanca Academic / other |
| Locations | 4 sites (Badalona, Barcelona and 3 other locations) |
| Trial ID | NCT06379945 on ClinicalTrials.gov |
What this trial studies
The UMBRELLA-SUMMA project aims to enhance the clinical management of Myelodysplastic Syndromes (MDS) in Spain through advanced diagnostic and prognostic techniques. It utilizes Optical Genome Mapping (OGM) to identify chromosomal alterations in MDS patients, particularly in cases where traditional methods fail. Additionally, the project expands access to Next Generation Sequencing (NGS) for prognostic stratification and employs Artificial Intelligence to refine prognostic models. This initiative is supported by a collaboration of over 400 professionals across more than 100 centers in Spain.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with a confirmed diagnosis of Myelodysplastic Syndromes.
Not a fit: Patients under 18 years old or those who do not provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this project could lead to more accurate diagnoses and personalized treatment plans for MDS patients, improving their overall outcomes.
How similar studies have performed: Other studies utilizing advanced genomic technologies and AI in hematologic malignancies have shown promising results, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years old * Patients with a confirmed diagnosis of MDS by cytogenetics and/or morphological analysis * Patients with complete clinical data * Patients who sign the informed consent Exclusion Criteria: * Patients under 18 years old * Patients who do not sign the informed consent
Where this trial is running
Badalona, Barcelona and 3 other locations
- Fundación Instituto de Investigación Germans Trias i Puyol — Badalona, Barcelona, Spain (Recruiting)
- Hospital Universitario Vall d´Hebron — Barcelona, Spain (Recruiting)
- Clínica Universitaria de Navarra — Pamplona, Spain (Recruiting)
- Complejo Asistencial Universitario de Salamanca — Salamanca, Spain (Recruiting)
Study contacts
- Study coordinator: María Díez Campelo, PhD MD
- Email: mdiezcampelo@usal.es
- Phone: +34 923 29 11 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.